Economic Evaluation of the Use of Nadroparin Calcium in the Prophylaxis of Deep Vein Thrombosis and Pulmonary Embolism in Surgical Patients in Italy

1997 ◽  
Vol 12 (4) ◽  
pp. 475-485 ◽  
Author(s):  
Adam Lloyd ◽  
Judith A. Aitken ◽  
Ullrich K.O. Hoffmeyer ◽  
Emma J. Kelso ◽  
Elizabeth C. Wakerly ◽  
...  
1998 ◽  
Vol 4 (2) ◽  
pp. 96-104
Author(s):  
Russell D. Hull ◽  
Graham F. Pineo

Pulmonary embolism remains a major cause of death in high-risk medical and surgical patients. This is unfor tunate as effective measures for prevention of venous throm boembolism in such patients are now available. Based on Level 1 evidence from clincial trials and systematic reviews, recom mendations can be made for the prevention of venous throm boembolism in most situations. If such information is not avail able, recommendations based on extrapolation from similar risk situations or from consensus opinions must be used. Additional clinical trials are required to fill in such gaps in our knowledge and permit adequate protection against fatal pulmonary embo lism in most if not all medical and surgical patients. Key Words: Heparin—Low molecular weight heparin—Oral anti coagulants—Intermittent pneumatic compression—Graduated compression stockings—Deep vein thrombosis—Pulmonary embolism.


1992 ◽  
Vol 30 (3) ◽  
pp. 9-12

Deep vein thrombosis (DVT) is a common event in hospital patients.1 The diagnosis is often missed, and its most serious sequel, fatal pulmonary embolism (PE) is still detected in 10% of hospital autopsies.2–3 DVT also commonly leads to chronic venous insufficiency and venous ulceration, treatment of which costs the NHS about £600 million a year.4 Deep vein thrombosis can be prevented in 60–75% of surgical patients,5 but many different prophylactic regimens are used, and some surgeons still use none.6 We discuss here who should receive prophylaxis, how it should be given, and review the treatment of established venous thrombosis.


Sign in / Sign up

Export Citation Format

Share Document